Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $60.60, above its previous 52-week high of $60.57 with 236,666 shares traded as of 10:10 a.m. ET. Average volume has been 2.5 million shares over the past 30 days.
Covidien has a market cap of $28.73 billion and is part of the
industry. Shares are up 33% year to date as of the close of trading on Thursday.
Covidien Public Limited Company develops, manufactures, and sells healthcare products for use in clinical and home settings in the United States and internationally. The company has a P/E ratio of 15.4, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Covidien as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full
52-week high stocks
or get investment ideas from our
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now